BIOX
Get informed when a big investor buys or sells
+ FollowOvervalued by 3296.1% based on the discounted cash flow analysis.
| Market cap | $22.78 Million |
|---|---|
| Enterprise Value | $250.48 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.74 |
| Beta | 0.43 |
| Outstanding Shares | 63,600,000 |
| P/E Ratio | -0.1 |
|---|---|
| PEG | 0.27 |
| Price to Sales | 0.11 |
| Price to Book Ratio | 0.34 |
| Enterprise Value to Revenue | 1.02 |
| Enterprise Value to EBIT | -33.44 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.95 |
| Debt to Equity | 6.11 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0581▲ 5.81% |
|---|---|
| Total Calls | 199,500▲ 1576.47% |
| Total Puts | 11,600▲ Infinity% |
Holdings and activity of institutional investors.
| Ownership % | 13.24%▼ 1.30% |
|---|---|
| Total Invested | $2.95M▼ 28.29% |
| Investors Holding | 30▼ 1.00% |
No data